Search for: "Actavis"
Results 281 - 300
of 1,006
Sorted by Relevance
|
Sort by Date
15 Aug 2019, 11:16 am
Actavis Laboratories FL, Inc. [read post]
4 Dec 2014, 5:00 am
Bruce H. [read post]
14 Mar 2012, 10:00 pm
Nous avions vu le mois dernier que la CJUE avait été saisie d'une question préjudicielle relative à l'interprétation des articles 4 et 5 du règlement sur les CCP. [read post]
12 Aug 2014, 9:55 pm
Both these assumptions are thrown into doubt by the Patent Court's decision in Actavis v Eli Lilly[2]. [read post]
1 Jul 2013, 9:59 pm
Actavis, Inc. and Mutual Pharmaceutical Co. v. [read post]
11 Oct 2013, 9:34 pm
The American Bar Association (ABA) Section of Intellectual Property Law, Young Lawyers Division, and Center for Professional Development will be offering a live webinar on "Reverse-Payment License Agreements: A Review of the Hatch-Waxman Act Post-Actavis" on October 22, 2013 from 2:00 to 3:30 pm (Eastern). [read post]
30 Dec 2012, 9:30 pm
Actavis Inc. 1:12-cv-01750; filed December 21, 2012 in the District Court of Delaware Infringement of U.S. [read post]
2 May 2014, 9:43 am
The FTC brief explains that the no-authorized-generic (no-AG) commitment at issue raises the same antitrust concern that the Supreme Court identified in Actavis. [read post]
16 May 2014, 9:45 pm
The conference will provide optimal strategies to help attendees maximize their patent portfolios, including: • The radical SPC decisions in Georgetown University, Actavis and Eli Lilly; • Capitalise on second medical use patents by implementing proven strategies and utilising tactical enforcement and remedial methods; • Fundamental update on the imminent Unitary Patent and Unified Patent Court and how to adapt business strategies effectively; • The 'Right' to… [read post]
27 Feb 2013, 9:41 pm
Actavis Inc. et al. [read post]
19 Sep 2023, 8:34 pm
Noonan -- A decade ago the Federal Trade Commission engaged in a crusade against reverse settlement payment agreements in ANDA litigation (which they termed, Madison Avenue-like, "pay for delay" settlements), arguing that such agreements were per se antitrust violations, despite almost universal rejection of their position by most Courts of Appeal prior to the Supreme Court's decision in Actavis v FTC. [read post]
2 Mar 2014, 8:47 pm
.; Actavis Inc. [read post]
12 Oct 2020, 9:59 pm
Noonan -- The Federal Trade Commission carried out an (in)famous crusade against reverse payment (more provocatively, "pay for delay") settlements in ANDA litigation for almost a decade before eventually having the Supreme Court see things their way (to some extent) in FTC v Actavis. [read post]
25 Feb 2020, 9:03 am
Actavis Laboratories UT, Inc., with Judges Newman, O’Malley, Stoll and Lourie dissenting. [read post]
9 Sep 2014, 9:59 pm
Actavis, in this action the Commission has expanded its allegations of anticompetitive behavior beyond cash payments from branded to generic drug companies (provocatively termed "pay-for-delay" agreements) to other forms of agreements (and not for the first time). [read post]
10 Jun 2014, 5:25 pm
., Actavis, Inc., Watson Laboratories,Inc., and Watson Pharma, Inc. [read post]
30 Sep 2013, 4:50 am
Mark Lemley's Firm Files DJ Against Myriad in Northern California ----- Promise Not to Infringe Insufficient in ANDA Litigation ----- Licensing Deals Stall in Pharmaceutical Sector in First Half of 2013 ----- Mylan Settles with FTC over Agila Acquisition from Strides ----- Amgen and ShanghaiTech University Announce China R&D Center ----- Forest Laboratories sues over SAVELLA® generics ----- Teva Pharmaceutical scores patent cictory over Mylan on AZILECT® ----- Patent Awarded to New… [read post]
13 Mar 2016, 7:00 am
Actavis has given the FTC a greater capacity to challenge pay for delay schemes in court. [read post]
11 Apr 2015, 8:45 pm
Sandoz and the Impact of a New Claim Construction Standard of Review • Personal and General Jurisdiction Challenges Under Daimler and Mylan • Myriad 101 Rejections and Nautilus 112 Indefiniteness Findings • Barraclude and New Obviousness Considerations • IPR, CBM, and PGR Utilization in ANDA Litigation • Reissue Applications as a Cure for Invalidity Findings • Akamai's Effect on Method of Treatment Claims and Carve-Outs • Settlement Strategies… [read post]
5 Feb 2019, 9:59 pm
They also found that even if the claims had been found valid, they would not have been infringed by Actavis and Mylan's activities, and that the post-trial amendment to try to limit the... [read post]
